VIDEO: Positioning complement inhibitors for treatment of glomerular diseases

Editor’s note: This is an automatically generated transcript. Please notify editor@healio.com if there are concerns regarding accuracy of the transcription.

The complement inhibitors are the latest drugs that are coming to the market. It's hard to say how to position them because it really depends on what disease we are talking about. So in C3 glomerulopathy or atypical HUS or in IGA space now in ANCA vasculitis, these drugs are sort of booming.

There are certain other diseases but they're not really used as much. Many of these diseases, these complement inhibitors are used in the initial induction phase to get the immunity suppressed quickly so that people can go into remission quickly. I will also say that there are also other clinical trials that are happening in this area.

And so my goal is what works best for my patient in front of me? What disease do they have, how involved is their disease, what else is getting involved, what are the comorbid conditions, is this the induction phase, do they qualify for a clinical trial, do we have a clinical trial? So all of these factors go into the decision about complement inhibitors.